Marc Johnson, MD
Adult Medicine · Fort Worth, TXNPI 1730475815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Viiv Healthcare Company at 33.7% of the total. Reporting peaked in 2019 at $1,661 and has fallen 68.0% since, to $532 in 2025.
Across 269 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- AstraZeneca$796
- Gilead$553
- Boehringer Ingelheim$316
- GSK$307
- Novo Nordisk$296
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,66699%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 64 | $1,933 |
| AstraZeneca | 56 | $796 |
| Gilead | 9 | $553 |
| Boehringer Ingelheim | 22 | $316 |
| GSK | 25 | $307 |
| Novo Nordisk | 18 | $296 |
| Merck | 12 | $262 |
| Johnson & Johnson(2 entities) | 19 | $250 |
| Theratechnologies Inc. | 4 | $143 |
| Insmed, Inc. | 1 | $111 |
| Insulet Corporation | 1 | $109 |
| Dexcom, Inc. | 1 | $107 |
| Sanofi-aventis U.S. LLC | 7 | $90 |
| AbbVie(2 entities) | 5 | $74 |
| Janssen Products, LP | 1 | $50 |
| Hikma Pharmaceuticals USA | 2 | $42 |
| Lilly USA, LLC | 3 | $40 |
| Shire North American Group Inc | 3 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $32 |
| Genentech USA, Inc. | 2 | $26 |
| Pfizer | 2 | $25 |
| Amgen | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $23 |
| Inari Medical, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,738 in reported general payments places this provider in the 85th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 187 | $729,698 |
| DovatoDolutegravir Sodium/Lamivudine | 105 | $313,335 |
| JulucaDolutegravir/Rilpivirine | 65 | $233,039 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 47 | $208,775 |
| TivicayDolutegravir Sodium | 86 | $205,206 |
| DescovyEmtricitabine/Tenofov Alafenam | 59 | $133,323 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 33 | $114,654 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $89,978 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 20 | $83,319 |
| PifeltroDoravirine | 26 | $52,038 |
| PrezcobixDarunavir/Cobicistat | 17 | $44,968 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 15 | $42,450 |
| OzempicSemaglutide | 14 | $18,279 |
| TrulicityDulaglutide | 13 | $16,663 |
| JanuviaSitagliptin Phosphate | 11 | $15,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $553 | $946,339266 claims |
| Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq | $1,933 | $866,234289 claims |
| Janssen Products, LPSymtuza | $50 | $208,77547 claims |
| MerckPifeltro, Delstrigo, Januvia | $262 | $110,05252 claims |
| Johnson & JohnsonPrezcobix | $250 | $44,96817 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $316 | $18,40423 claims |
| Novo NordiskOzempic | $296 | $18,27914 claims |
| Lilly USA, LLCTrulicity | $40 | $16,66313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Fort Worth
- Henry DollahiteFort Worth$621
- Darniece Christian PeoplesFort Worth$493
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.